Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
gptkb:NUC-1031
|
| gptkbp:CASNumber |
1626780-59-7
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2023)
|
| gptkbp:developedBy |
gptkb:NuCana
|
| gptkbp:drugClass |
antiviral drug
|
| https://www.w3.org/2000/01/rdf-schema#label |
Acelarin
|
| gptkbp:intendedUse |
gptkb:cancer
|
| gptkbp:mechanismOfAction |
inhibits DNA synthesis
|
| gptkbp:relatedTo |
gemcitabine
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational drug
|
| gptkbp:target |
gptkb:biliary_tract_cancer
pancreatic cancer |
| gptkbp:bfsParent |
gptkb:NuCana
|
| gptkbp:bfsLayer |
7
|